کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3323850 1211944 2016 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Controversies in antiplatelet therapy in the secondary prevention of stroke
ترجمه فارسی عنوان
اختلاف نظر در درمان ضد ترومبوتیک در پیشگیری ثانویه سکته مغزی
کلمات کلیدی
آسپرین کلوپیدوگرل، سیلوستازول، دیپیریدامول، سکته مغزی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی طب سالمندان و علم پیری شناسی
چکیده انگلیسی
Recurrence of stroke has been estimated at 3-4% yearly after TIA or stroke. There is no clear agreement in choosing antiplatelet therapy at this time. Europeans, Americans and British guidelines have been different. Aspirin is still used in secondary prevention of ischemic stroke, because of the longest experience with the best-achieved results in different studies and low price. Other used drugs are a combination of aspirin and dipyridamole, P2Y12 receptor antagonists - clopidogrel, ticlopidine, prasugrel and ticagrelor, or inhibitor of phosphodiesterase cilostazol, which was effective with Chinese and Japanese population. The common agreement is not to use a dual antiplatelet therapy in long term, because it does not carry a higher reduction of ischemic attacks than monotherapy. The other negative effect is causing more incidents with severe hemorrhage. According to the American recommendation, the combined therapy is promising early after having TIA and light stroke when the risk of recurrence of stroke is high.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Geriatric Medicine - Volume 7, Issue 1, February 2016, Pages 65-69
نویسندگان
,